Larimar Therapeutics (NASDAQ:LRMR) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Larimar Therapeutics (NASDAQ:LRMR) to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.70) EPS.

Several other research firms have also recently commented on LRMR. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Leerink Partners upgraded Larimar Therapeutics to a “strong-buy” rating in a research report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Larimar Therapeutics has an average rating of “Buy” and an average target price of $16.14.

Larimar Therapeutics Price Performance

LRMR opened at $5.52 on Tuesday. The stock has a market capitalization of $456.95 million, a P/E ratio of -2.86 and a beta of 1.00. The company’s 50 day simple moving average is $3.53 and its 200-day simple moving average is $3.79. Larimar Therapeutics has a one year low of $1.61 and a one year high of $6.42.

Institutional Trading of Larimar Therapeutics

A number of hedge funds have recently modified their holdings of LRMR. CWM LLC increased its stake in Larimar Therapeutics by 10.3% in the third quarter. CWM LLC now owns 36,013 shares of the company’s stock valued at $116,000 after purchasing an additional 3,361 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Larimar Therapeutics by 75.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after buying an additional 4,376 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in shares of Larimar Therapeutics by 33.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock valued at $59,000 after buying an additional 4,619 shares in the last quarter. Velan Capital Investment Management LP raised its stake in Larimar Therapeutics by 17.9% during the 2nd quarter. Velan Capital Investment Management LP now owns 33,000 shares of the company’s stock worth $95,000 after buying an additional 5,000 shares during the period. Finally, American Century Companies Inc. lifted its holdings in Larimar Therapeutics by 7.8% during the second quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock worth $200,000 after acquiring an additional 5,001 shares in the last quarter. 91.92% of the stock is currently owned by institutional investors and hedge funds.

Larimar Therapeutics News Roundup

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: Lifesci Capital upgraded LRMR to a “Strong-Buy” and published Q4 2025 and FY2025 EPS estimates (Q4: ($0.41); FY2025: ($1.70)), signaling analyst confidence in the company’s outlook and supporting demand for the shares. MarketBeat Lifesci Note
• Positive Sentiment: Citigroup raised its price target to $14 (buy), and Wedbush reaffirmed an outperform rating with an $11 target — both represent substantial upside vs. the current level and underpin bullish analyst sentiment. Benzinga
• Positive Sentiment: Unusually large call-option activity occurred (several thousand calls bought), suggesting short-term bullish positioning by traders and contributing to intraday spikes before the equity raise announcement. (No direct article link provided)
• Positive Sentiment: Coverage and commentary explaining the intraday rally were published (coverage noted a ~22% intraday rise before the selloff), which can attract momentum buyers and increased attention. AAII Article
• Neutral Sentiment: The company initially announced a proposed $75M underwritten offering (preliminary press release) — this first filing signaled capital raise intent before the deal was upsized. GlobeNewswire – Proposed Offering
• Negative Sentiment: Larimar priced an upsized underwritten public offering of 20,000,000 shares at $5.00 per share (gross proceeds ~$100M) and granted a 30-day option for an additional 3,000,000 shares — direct dilution and increased share supply are the main catalysts pressuring the stock. GlobeNewswire – Priced Offering

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.